<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">38713950</PMID><DateCompleted><Year>2024</Year><Month>06</Month><Day>02</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1950-6007</ISSN><JournalIssue CitedMedium="Internet"><Volume>175</Volume><PubDate><Year>2024</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Biomedicine &amp; pharmacotherapy = Biomedecine &amp; pharmacotherapie</Title><ISOAbbreviation>Biomed Pharmacother</ISOAbbreviation></Journal><ArticleTitle>Kokusaginine attenuates renal fibrosis by inhibiting the PI3K/AKT signaling pathway.</ArticleTitle><Pagination><StartPage>116695</StartPage><MedlinePgn>116695</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.biopha.2024.116695</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0753-3322(24)00579-1</ELocationID><Abstract><AbstractText>Kokusaginine is an active ingredient alkaloid that has been isolated and extracted from Ruta graveolens L. Some researches have indicated that alkaloids possess anti-inflammatory and antioxidant effects. Nevertheless, the potential nephroprotective effects of kokusaginine on renal fibrosis remain undetermined. This study was conducted to examine the protective effect of kokusaginine on renal fibrosis and to explore the underlying mechanisms using both in vivo and in vitro models. Renal fibrosis was induced in male C57BL/6&#x202f;J mice by feeding with 0.2% adenine-containing food and UUO surgery. Kokusaginine was administered orally simultaneously after the establishment of renal fibrosis. Renal function was measured by serum levels of creatinine and urea nitrogen. Renal pathological changes were assessed by HE staining and Masson staining. Western blotting was employed to detect the expression levels of fibrosis-related proteins in mice and cells. Additionally, network pharmacology analysis and RNA-seq were utilized to predict the pathways through which kokusaginine could exert its anti-fibrotic effects. The treatment with kokusaginine enhanced renal function, alleviated renal histoarchitectural lesions, and mitigated renal fibrosis in the renal fibrosis models. The network pharmacology and RNA-seq enrichment analysis of the KEGG pathway demonstrated that kokusaginine could exert anti-renal fibrosis activity via the PI3K/AKT signaling pathway. And the results were verified in both in vitro and in vivo experiments. In conclusion, our data implied that kokusaginine inhibited the activation of the PI3K/AKT signaling pathway both in vitro and in vivo, and suppressed the formation of renal fibrosis. Thus, the kokusaginine-mediated PI3K/AKT signaling pathway may represent a novel approach for the treatment of renal fibrosis.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024 The Authors. Published by Elsevier Masson SAS.. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yuxin</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, Xiangya Hospital, Central South University,&#xa0;Changsha,&#xa0;China; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University,&#xa0;Changsha 410008,&#xa0;China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Han</LastName><ForeName>Yuanyuan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Hunan Key Laboratory of Organ Fibrosis, Central South University,&#xa0;Changsha,&#xa0;China; Department of Nephrology, Xiangya Hospital, Central South University, Changsha, China, Central South University,&#xa0;Changsha,&#xa0;China; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University,&#xa0;Changsha 410008,&#xa0;China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shang</LastName><ForeName>Kaiqi</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, Xiangya Hospital, Central South University,&#xa0;Changsha,&#xa0;China; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University,&#xa0;Changsha 410008,&#xa0;China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xiao</LastName><ForeName>Jing</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Hunan Institute for Drug Control,&#xa0;Changsha 410001, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tao</LastName><ForeName>Lijian</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Hunan Key Laboratory of Organ Fibrosis, Central South University,&#xa0;Changsha,&#xa0;China; Department of Nephrology, Xiangya Hospital, Central South University, Changsha, China, Central South University,&#xa0;Changsha,&#xa0;China; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University,&#xa0;Changsha 410008,&#xa0;China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peng</LastName><ForeName>Zhangzhe</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Hunan Key Laboratory of Organ Fibrosis, Central South University,&#xa0;Changsha,&#xa0;China; Department of Nephrology, Xiangya Hospital, Central South University, Changsha, China, Central South University,&#xa0;Changsha,&#xa0;China; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University,&#xa0;Changsha 410008,&#xa0;China. Electronic address: pengzhangzhe@csu.edu.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Shao</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, Xiangya Hospital, Central South University,&#xa0;Changsha,&#xa0;China; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University,&#xa0;Changsha 410008,&#xa0;China. Electronic address: liushao999@csu.edu.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Yueping</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, Xiangya Hospital, Central South University,&#xa0;Changsha,&#xa0;China; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University,&#xa0;Changsha 410008,&#xa0;China. Electronic address: jiangyueping@csu.edu.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>05</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Biomed Pharmacother</MedlineTA><NlmUniqueID>8213295</NlmUniqueID><ISSNLinking>0753-3322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 2.7.1.-</RegistryNumber><NameOfSubstance UI="D019869">Phosphatidylinositol 3-Kinases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005355" MajorTopicYN="Y">Fibrosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007668" MajorTopicYN="Y">Kidney</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007674" MajorTopicYN="Y">Kidney Diseases</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000091484" MajorTopicYN="N">Network Pharmacology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019869" MajorTopicYN="Y">Phosphatidylinositol 3-Kinases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051057" MajorTopicYN="Y">Proto-Oncogene Proteins c-akt</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="Y">Signal Transduction</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Kokusaginine</Keyword><Keyword MajorTopicYN="N">Network pharmacology</Keyword><Keyword MajorTopicYN="N">PI3K/AKT signaling pathway</Keyword><Keyword MajorTopicYN="N">Renal fibrosis</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest We declare that we have no financial and personal relationships with other people or organizations that can inappropriately influence our work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>1</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>4</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>4</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>6</Month><Day>2</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>5</Month><Day>8</Day><Hour>2</Hour><Minute>5</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>5</Month><Day>7</Day><Hour>18</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38713950</ArticleId><ArticleId IdType="doi">10.1016/j.biopha.2024.116695</ArticleId><ArticleId IdType="pii">S0753-3322(24)00579-1</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>